dolutegravir - Books

Result Filters

Results: 1 to 20 of 85 books (697 items)

<< First< Prev

Page of 5

Next >Last >>

Select item 46653881.

Clinical Review Report: dolutegravir (Tivicay) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug.

Top results in this book Table of Contents

Select item 46952242.

Clinical Review Report: Dolutegravir/Rilpivirine (Juluca): (ViiV Healthcare): Indication: As a complete regimen to replace the current antiretroviral regimen for the treatment of HIV-1 infection in adults who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per mL) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jun.

Top results in this book Table of Contents

Select item 49066083.

Clinical Review Report: Dolutegravir/Lamivudine (Dovato): (ViiV Healthcare ULC): Indication: As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Oct.

Top results in this book Table of Contents

Select item 44036684.

StatPearls [Internet].

Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Top results in this book Table of Contents

Select item 47498585.

Clinical Review Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) (Biktarvy): (Gilead Sciences Canada, Inc.): Indication: A complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance to the individual components of Biktarvy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.

Top results in this book Table of Contents

Select item 48538166.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Top results in this book Table of Contents

Select item 49064967.

Pharmacoeconomic Review Report: Dolutegravir/Lamivudine (Dovato): (ViiV Healthcare ULC): Indication: As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Oct.

Top results in this book Table of Contents

Select item 50243428.

Selecting an Initial ART Regimen [Internet].

Urbina AE, Bradley N, Lee Y, et al.

Baltimore (MD): Johns Hopkins University; 2022 Aug.

Top results in this book Table of Contents

Select item 42965249.

Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. 2nd edition.

Geneva: World Health Organization; 2016.

Top results in this book Table of Contents

Select item 481204410.

Pharmacoeconomic Review Report: Doravirine (Pifeltro): (Merck Canada Inc.): Indication: Doravirine (Pifeltro) is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of viral resistance to doravirine [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jun.

Top results in this book Table of Contents

Select item 436619611.

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/COBI/FTC/TAF) (Genvoya) Fixed-Dose Combination, Oral Tablet) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Nov.

Top results in this book Table of Contents

Select item 469397212.

Pharmacoeconomic Review Report: Dolutegravir/Rilpivirine (Juluca): (ViiV Healthcare ULC): Indication: As a complete regimen to replace the current antiretroviral regimen for the treatment of HIV-1 infection in adults who are virologically stable and suppressed (HIV-1 RNA < 50 copies/mL) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jun.

Top results in this book Table of Contents

Select item 474970213.

Pharmacoeconomic Review Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) (Biktarvy): (Gilead Sciences Canada, Inc.): Indication: A complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance the individual components of Biktarvy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct.

Top results in this book Table of Contents

Select item 466803014.

Pharmacoeconomic Review Report: dolutegravir (Tivicay) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug.

Top results in this book Table of Contents

Select item 474656815.

Pharmacoeconomic Review Report: Emtricitabine/tenofovir alafenamide (Descovy) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug.

Top results in this book Table of Contents

Select item 543633416.

Second-Line ART After Treatment Failure or for Regimen Simplification [Internet].

McGowan JP, Vail RM, Shah SS, et al.

Baltimore (MD): Johns Hopkins University; 2024 Aug.

Top results in this book Table of Contents

Select item 549785817.

Fostemsavir (Rukobia): CADTH Reimbursement Review: Therapeutic area: Human immunodeficiency virus type 1 [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Jul.

Top results in this book Table of Contents

Select item 522920218.

Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach [Internet].

Geneva: World Health Organization; 2021 Jul.

Top results in this book Table of Contents

Select item 474093419.

Clinical Review Report: Emtricitabine/tenofovir alafenamide fumarate (Descovy) [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug.

Top results in this book Table of Contents

Select item 340129420.

Endotext [Internet].

Feingold KR, Anawalt B, Blackman MR, et al., editors.

South Dartmouth (MA): MDText.com, Inc.; 2000-.

Top results in this book Table of Contents

<< First< Prev

Page of 5

Next >Last >>

Supplemental Content

Images search in Bookshelf

F igure 2A Non-inferiority Plot for the SPRING-2 Study, Week 48

CI = confidence interval; DTG = dolutegravir; RAL = raltegravir.

Results.

Clinical Review Report: dolutegravir (Tivicay) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug.
F igure 4A Non-inferiority Plot for the SAILING Study, Week 48

CI confidence interval; DTG = dolutegravir; RAL = raltegravir

Results.

Clinical Review Report: dolutegravir (Tivicay) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug.
F igure 3A Non-inferiority Plot for the SINGLE Study, Week 48

CI = confidence interval; DTG = dolutegravir; EFV = efavirenz; FTC = emtricitabine; TDF = tenofovir.

Results.

Clinical Review Report: dolutegravir (Tivicay) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Aug.
Figure 2Study Design of the GEMINI-1 and GEMINI-2 Trials

3TC = lamivudine; DTG = dolutegravir; FDC = fixed-dose combination; FTC = emtricitabine; RNA = ribonucleic acid; TDF = tenofovir disoproxil fumarate.
Source: GEMINI-1 Clinical Study Report;¹¹ GEMINI-2 Clinical Study Report.¹²

Results.

Clinical Review Report: Dolutegravir/Lamivudine (Dovato): (ViiV Healthcare ULC): Indication: As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents 12 years of age and older and weighing at least 40 kg [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Oct.